Phenytoin as a last‐resort treatment in SCN8A encephalopathy. Issue 3 (16th May 2017)

• Record Type: Journal Article
• Authors: Braakman, Hilde M.; Verhoeven, Judith S.; Erasmus, Corrie E.; Haaxma, Charlotte A.; Willemsen, Marjolein H.; Schelhaas, H. Jurgen
• Is Part Of: Epilepsia open. Volume 2:Issue 3(2017)
• Page Start: 343
• Page End: 344
• Publication Date: 2017-05-16
• Subjects: SCN8A -- Phenytoin -- Epileptic encephalopathy; Epilepsy -- Periodicals; Epilepsy -- Research -- Periodicals; Epilepsy; Periodicals; Fulltext; Internet Resources; Periodicals; 616.853005
• DOI: 10.1002/epi4.12059
• Languages: English
• ISSNs: 2470-9239

Abstract

Summary: SCN8A encodes Nav1.6, one of the main voltage‐gated sodium channel subunits in the brain, and SCN8A mutations lead to epileptic encephalopathy. Particular mutations render the mutant channel more susceptible to inhibition by phenytoin. Yet, the potentially severe side effects of phenytoin maintenance therapy, especially cognitive impairment, are undesirable in these already cognitively impaired patients. We describe a 5‐year‐old patient with SCN8A encephalopathy in whom phenytoin proved successful as emergency treatment to prevent clustering of seizures and status epilepticus, thus hospital stays. The ketogenic diet, levetiracetam, zonisamide, topiramate, and phenytoin maintenance therapy resulted in adverse reactions not previously documented in SCN8A encephalopathy.